Corrigendum to “Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes” [International Journal of Cardiology 2023 Jan 15;371:293–294 10.1016/j.ijcard.2022.09.019 (International Journal of Cardiology (2023) 371 (293–294), (S0167527322013286), (10.1016/j.ijcard.2022.09.019))

Seferović, Petar M. (6603594879)Petar M. (6603594879)SeferovićPolovina, Marija (35273422300)Marija (35273422300)PolovinaSeferović, Jelena (23486982900)Jelena (23486982900)SeferovićRosano, Giuseppe (7007131876)Giuseppe (7007131876)Rosano2025-06-122025-06-122023https://doi.org/10.1016/j.ijcard.2023.02.016https://www.scopus.com/inward/record.uri?eid=2-s2.0-85148371648&doi=10.1016%2fj.ijcard.2023.02.016&partnerID=40&md5=f9f98d3de64cafde65c682416c900f74https://remedy.med.bg.ac.rs/handle/123456789/2781The authors regret the Funding section. The latter should read as follows: “This study was supported by the Italian Ministry of Health (Ricerca Corrente) 20/1819”. The authors would like to apologise for any inconvenience caused. © 2023 Elsevier B.V.Corrigendum to “Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes” [International Journal of Cardiology 2023 Jan 15;371:293–294 10.1016/j.ijcard.2022.09.019 (International Journal of Cardiology (2023) 371 (293–294), (S0167527322013286), (10.1016/j.ijcard.2022.09.019))